Omnicell upped from Hold to Buy by Craig-Hallum

Target $85

https://www.benzinga.com/stock/OMCL/ratings

Novocure cut to Neutral from Overweight by JPMorgan

Target to $79 from $61

https://www.benzinga.com/stock/NVCR/ratings

Nektar target cut to $79 from $81 by Mizuho

Maintains Buy

https://www.benzinga.com/stock/NKTR/ratings

Merit Medical cut to Market Perform from Outperform by Wells Fargo

https://www.benzinga.com/stock/MMSI/ratings

LabCorp target upped to $190 from $175 by Morgan Stanley

Maintains Overweight

https://www.benzinga.com/stock/LH/ratings

Gritstone Oncology started at Outperform by Baird

Target $17

https://www.benzinga.com/stock/GRTS/ratings

eHealth target raised to $120 from $100 by Cantor

Maintains Overweight

https://www.benzinga.com/stock/EHTH/ratings